Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Innovent Biologics Inc (OP: IVBXF )

4.850 -0.235 (-4.62%)
Streaming Delayed Price Updated: 10:20 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innovent Biologics Inc

< Previous 1 2 Next >
Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate
Privately-held UNION therapeutics A/S and Innovent Biologics Inc's (OTC: IVBIY) subsidiary have entered into a strategic collaboration and license... 
Via Benzinga
Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
Innovent Biologics Inc (OTC: IVBIY) and Bolt Biotherapeutics Inc (NASDAQ: BOLT) have entered into a drug research and development collaboration for oncology candidates. The... 
Via Benzinga
Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer
Innovent Biologics Inc (OTC: IVBIY) has announced topline results from Phase 3 ORIENT-16 study evaluating sintilimab, meeting the primary endpoint of overall... 
Via Benzinga
Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients
Innovent Biologics Inc (OTC: IVBIY) and Eli Lilly And Co (NYSE: LLY) have announced new and updated data from the ORIENT-11 Phase 3 study of sintilimab... 
Via Benzinga
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking... 
Via Benzinga
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC: IVBXF) and Eli Lilly And Co's (NYSE: LLY)... 
Via Benzinga
Lilly-Innovent's Sintilimab Plus Chemo Application For Lung Cancer Under Review With FDA
The FDA has accepted to review Innovent Biologics Inc (OTC: IVBIY) and Eli Lilly and Co's (NYSE: LLY) marketing application for sintilimab injection... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.